BackARS Pharmaceuticals Overview
ARS Pharmaceuticals Inc

ARS Pharmaceuticals Target Price

Where could SPRY trade next? Consensus target price: $15.

Get informed when a big investor buys or sells

+ Follow

Share Price

$4.17

Average Target Price

$15.00260.1% upside

1 analysts in the last 4 months

High: $15 | Low: $15

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-09-08Leerink Partners$15260.1% upsideOpen
2026-04-09Northland Securities$25500.2% upsideOpen
2026-03-10Leerink PartnersRoanna Ruiz$26524.2% upsideOpen
2025-11-04Roth CapitalKyle Bauser$30620.3% upsideOpen
2025-09-26Raymond James$32668.3% upsideOpen
2024-08-19Cantor FitzgeraldJosh Schimmer$30620.3% upsideOpen
2024-08-12Raymond JamesStrong Buy$22428.2% upsideOpen
2024-07-25Raymond JamesRyan Deschner$18332.2% upsideOpen
2024-03-05Leerink PartnersRoanna Ruiz$18332.2% upsideOpen
2022-12-13Leerink Partners$14236.1% upsideOpen

ARS Pharmaceuticals (SPRY) FAQ

As of the most recent data, SPRY shows a target price of $15. Scroll down for historical charts and peer comparison views.

If ARS Pharmaceuticals moved to the average analyst target of $15, shares would be roughly 260.1% higher than $4.17. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of ARS Pharmaceuticals's earnings trajectory.

Besides this target price page, Stockcircle has ARS Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $15) with ownership activity and broader fundamentals.

ARS Pharmaceuticals's target price is $15; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.